Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
Cybin continues to make significant progress on its journey to bring breakthrough therapies to patients by delivering on the following key milestones
Article content
– Received European and United Kingdom Medical and Healthcare Products Regulatory Agency ('MHRA') approval for EMBRACE, the Company's second pivotal study evaluating CYB003 for the adjunctive treatment of Major Depressive Disorder ('MDD') on schedule –
Article content
Article content
– EMBRACE study to enroll 330 participants at approximately 60 clinical sites across
Article content
the United States, United Kingdom, Europe, and Australia 1 –
Article content
– Completion of patient enrollment in CYB004 Phase 2 study in General Anxiety Disorder expected in August 2025 1 –
Article content
– Recent financing agreement of US$50 million principal amount of convertible debentures will advance clinical pipeline programs –
Article content
– Cash totaled US$118.7 million as of June 30, 2025 –
Article content
This news release constitutes a 'designated news release' for the purposes of Cybin's prospectus supplement dated February 10, 2025, to its short form base shelf prospectus dated August 17, 2023, as amended December 22, 2023, April 8, 2024, and January 6, 2025.
Article content
TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its first quarter ended June 30, 2025, and is pleased to provide an update on key business milestones.
Article content
'With our recently announced funding agreement in place, we are well positioned to continue advancing our lead clinical programs, CYB003 and CYB004, through multiple inflection points,' said Doug Drysdale, Chief Executive Officer of Cybin. 'Gaining European CTA approval and MHRA approval to commence EMBRACE in the UK has enabled us to expand our multinational Phase 3 PARADIGM program evaluating CYB003 for the potential adjunctive treatment of major depressive disorder. PARADIGM is a significantly larger program than the completed Phase 2 study, with anticipated combined enrollment of approximately 550 participants. Our Phase 3 studies will evaluate the potential clinical benefits of CYB003 in patients living with moderate to severe MDD, and whose symptoms are uncontrolled with existing antidepressant treatment. Our Phase 2 study evaluating CYB004 in generalized anxiety disorder is expected to complete patient enrollment this month.'
Article content
'Cybin is in a strong position to advance our programs and continue our work to deliver innovative therapies to address some of the most challenging mental health disorders we face today and is helping to build momentum across the sector – both from a clinical and regulatory perspective,' concluded Drysdale.
Article content
Recent Business and Pipeline Highlights:
Article content
Received European approval and MHRA approval for EMBRACE, the second Phase 3 study within the PARADIGM program evaluating CYB003 for the adjunctive treatment of MDD, on schedule.
Article content
The Company has received CTA approval from the Irish Medicines Board for the EMBRACE study in Ireland, Poland, and Greece, as well as approval from the MHRA.
Article content
Article content
EMBRACE is a 12-week, randomized, double-blind, placebo-controlled study in 330 participants with moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but with inadequate response. EMBRACE will evaluate two doses of CYB003 (8 mg, 16 mg) three weeks apart, compared to an inactive placebo. The primary endpoint is change in depressive symptoms as measured by the change in MADRS from baseline six weeks after the first dose.
Article content
Making strong progress on CYB003 development through the APPROACH and EXTEND studies.
Article content
Dosing is currently ongoing in the first pivotal study, APPROACH, which is expected to enroll 220 patients across 45 U.S. clinical sites. We are pleased to report that patient rollovers continue into EXTEND, the long-term extension study.
Article content
Clinical Program Summary
Article content
CYB003 program accomplishments:
Article content
Received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of MDD.
A completed Phase 2 study of CYB003 in MDD demonstrated durability of effect at 12 months:
100% of participants receiving two doses of 16 mg were responders.
71% of participants receiving two doses of 16 mg were in remission.
Mean change from baseline in MADRS was approximately -23 points after two 16 mg doses.
Article content
CYB004: Deuterated dimethyltryptamine program
Article content
The Phase 2 CYB004 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with generalized anxiety disorder, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed. Patient enrollment is expected to be completed this month 1.
Article content
Change in Presentation Currency
Article content
Effective April 1, 2025, the Company changed its presentation currency from the Canadian dollar to the United States dollar (' USD '). The change in presentation currency was made to better reflect the Company's operations, align with the currency in which the majority of cash-based expenses are denominated, and improve comparability of its financial results with other publicly traded businesses in the industry. As a result, all amounts presented in this press release are in USD unless otherwise stated.
Article content
First-Quarter Financial Highlights
Article content
Cash totaled $118.7 million as of June 30, 2025.
Net loss was $24.6 million for the quarter ended June 30, 2025, compared to a net loss of $10.8 million in the same period last year.
Cash-based operating expenses consisting of research, general, and administrative costs totaled $23.9 million for the quarter ended June 30, 2025, compared to $11.9 million, in the same period last year.
Cash flows used in operating activities were $29.5 million for the quarter ended June 30, 2025, compared to $19.9 million in the same period last year.
Article content
About Cybin
Article content
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
Article content
With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Article content
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
Note:
Article content
Cautionary Notes and Forward-Looking Statements
Article content
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia; the Company's expectation to enroll 220 participants at approximately 45 clinical sites across the United States for the APPROACH study; the Company's expectation to complete enrollment in CYB004 Phase 2 study in August 2025; the Company's expectation to receive topline data from APPROACH in 2026; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
Article content
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2025, and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Article content
Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Investor & Media Contact:
Article content
Article content
Gabriel Fahel
Article content
Article content
Chief Legal Officer
Article content
Article content
Cybin Inc.
Article content
Article content
1-866-292-4601
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
29 minutes ago
- Globe and Mail
From Tradition to Trend: Chinese Confinement Nannies Gain Popularity Across the U.S.
"A Chinese confinement nanny in her 50s gently holds a Chinese-American newborn in a modern living room. This is the currently growing trend of traditional postpartum care in the United States" The centuries-old tradition of Chinese postpartum confinement is going mainstream in America, as more families seek culturally rooted newborn care and maternal recovery support. LOS ANGELES, CA - August 15, 2025 - The centuries-old practice of zuo yue zi — or Chinese postpartum confinement — is no longer limited to the Asian community. Families across the United States are increasingly hiring Chinese confinement nannies to ensure mothers receive proper rest, nutrition, and newborn care during the critical first 30 to 100 days after birth. 'Postpartum care is about more than changing diapers — it's about a mother's physical healing, emotional stability, and family bonding,' said Stephanie Lin, founder of My Asian Nanny. 'We've seen a 40% increase in inquiries from non-Asian families over the past three years, especially in major metro areas.' The growing interest reflects a wider shift in attitudes toward postpartum recovery, as more parents seek holistic and culturally informed support. Confinement nannies typically provide round-the-clock newborn care, traditional healing meals, lactation support, and gentle postpartum exercises to aid recovery. The trend is supported by research showing that mothers who receive consistent postpartum care report faster physical recovery, lower stress levels, and a reduced risk of postpartum depression. Parents can learn more or request a nanny by completing the Family Registration Intake Form. About My Asian Nanny My Asian Nanny is a U.S.-based referral agency specializing in postpartum confinement nannies and newborn care. Serving families nationwide, the agency connects clients with experienced caregivers who provide round-the-clock support, traditional postpartum meals, and expert newborn handling. Media Contact Company Name: My Asian Nanny Contact Person: Stephanie Lin Email: Send Email Phone: 6269887577 Address: 216 west Garvey Avenue Unit G City: Monterey Park State: CA Country: United States Website:
Globe and Mail
32 minutes ago
- Globe and Mail
Smith & Nephew (SN) Receives a Hold from Stifel Nicolaus
Stifel Nicolaus analyst Dylan Van Haaften maintained a Hold rating on Smith & Nephew today and set a price target of £14.15. The company's shares closed today at p1,353.00. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Van Haaften covers the Healthcare sector, focusing on stocks such as Merck KGaA, Smith & Nephew, and Sartorius. According to TipRanks, Van Haaften has an average return of -5.5% and a 32.65% success rate on recommended stocks. In addition to Stifel Nicolaus, Smith & Nephew also received a Hold from Berenberg Bank's Sam England in a report issued on August 11. However, yesterday, Bank of America Securities reiterated a Buy rating on Smith & Nephew (LSE: SN). SN market cap is currently £11.76B and has a P/E ratio of 30.99. Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SN in relation to earlier this year.
CTV News
3 hours ago
- CTV News
What a Russia-Ukraine ceasefire deal could mean for global markets
Stock price information is displayed on screens as they hang above the Paris stock exchange, operated by Euronext NV, in La Defense business district in Paris, France. LONDON — World markets are watching closely as U.S. President Donald Trump and Russian President Vladimir Putin meet in Alaska later on Friday to seal a possible ceasefire agreement in Ukraine. This is a conflict that sparked an energy shock, sent food prices soaring, battered European assets and cut Russia's economy off from much of the Western world. Details and the longevity of any agreement will be key, and for now investors are on standby. Ukraine's government bonds - key indicators of the mood - in recent days have largely stalled at a still-distressed 55 cents on the dollar. 'The big issue will be, of course, that even if we get a ceasefire, how sustainable is that?' said Zurich Insurance Group's chief markets strategist Guy Miller. Here is a summary of how Europe's biggest conflict since the Second World War has shaped markets and what impact a ceasefire agreement could have. Europe hurt Europe's reliance on cheap Russian gas meant its economy and stock market were ill-equipped to handle surging energy prices, and Germany's economy, Europe's industrial powerhouse, stagnated. Stocks were broadly punished, with sectors reliant on low energy prices, such as industrials and chemicals, notably hit. European banks also took a drubbing but have since recovered as those exposed to Russia cut ties. It has not been all doom and gloom and the European index is not far off March's record high. Aerospace and defense stocks have had a supercharged rally since February 2022, with gains ranging from over 600 per cent for Leonardo to over 1,500 per cent for Rheinmetall. 'If the fighting stops in Ukraine, I'd expect defense stocks to come off a little bit but I think the fundamental reason why defense stocks have rallied is still there,' said Toni Meadows, CIO at BRI Wealth Management. 'If Putin is still there and Trump is still there, then the need for Europe to spend on defense is still there.' Heated The invasion triggered a surge in European energy prices. Brent crude rose as much as 30 per cent to US$139 a barrel, while natural gas prices soared nearly 300 per cent to record highs. Crude subsided in the following months. But Dutch futures, the regional benchmark for natural gas, soared as Europe scrambled for an alternative to the Russian gas that fed over 40 per cent of total demand. Europe has since become increasingly reliant on U.S. super-chilled liquefied natural gas. The European Union has committed to boosting its purchases of U.S. crude, gas and coal from around $75 billion in 2024 to $250 billion per year to 2027, under a new U.S. trade deal - a figure most experts say is unrealistic. Oil and gas prices are below 2022 peaks, but they are higher than five years ago, up 50 per cent and 300 per cent, respectively. Genie out of the bottle Following the COVID-19 pandemic, the war ensured the inflation genie was well out of its bottle as energy and food prices soared while agricultural exports from Russia and Ukraine - two leading grain exporters - were disrupted. Central banks backtracked on the notion that an inflation spike was 'transitory' and aggressive interest rate hikes followed. Since late 2022, inflation and rates have come down in big economies and focus shifted to U.S. tariffs. High food prices remain a concern, especially for developing economies. World food commodity prices rose in July to their highest in over two years, according to the United Nations' Food and Agriculture Organization. 'If Ukraine could operate normally as an economy, that would help food prices around the world,' said April LaRusse, head of investment specialists at Insight Investment. Ukraine and Russia Ukraine's economy was battered by the war. The country was forced to restructure $20 billion of its government debt last year as it could no longer afford the repayments given the demands of the conflict. Its bonds then rallied on hopes that a re-elected Trump would broker a peace deal but plunged following increasingly ugly exchanges between Trump and Ukraine's Volodymyr Zelenskyy that culminated in February's infamous Oval Office meeting. The bonds recovered some ground again this week. Russia's economy also contracted after the West introduced sweeping sanctions but soaring defense spending led to a rebound in 2023 and 2024. After jacking up rates to combat the subsequent inflation spike though, some Russian officials now warn of recession risks. Russia's rouble sank to a record low soon after the invasion, but rebounded to seven-year highs later in 2022 as imports dried up. It is up nearly 40 per cent against the dollar this year. Russia and China meanwhile now do more of their trade in the yuan, which has overtaken the dollar as Russia's most traded foreign currency. Currencies upended The war hit the euro, which fell almost six per cent against the U.S> dollar in 2022 as the economic impact was felt. Analysts say any improving sentiment created by a ceasefire could help the euro, but note that other factors, such as monetary policy were also key. 'The euro might benefit, but we wouldn't see this as a game changer for the currency,' said Frederique Carrier, head of investment strategy for RBC Wealth Management in the British Isles and Asia. While safe-havens such as the dollar and Swiss franc benefited, the conflict shaped currencies in other ways. Analysts say the use of sanctions against Russia and a decision by the West to freeze some $300 billion of Russian state assets in 2022 has accelerated de-dollarisation, in short, efforts by countries to decrease reliance on the dollar. (Reporting by Amanda Cooper, Marc Jones, Dhara Ranasinghe, Samuel Indyk, additional reporting by Alexander Marrow, Compiled by Dhara Ranasinghe; Editing by Tomasz Janowski)
